No abstract

No abstract

No abstract

Hemorrhagic diathesis due to anti‐factor XIII (FXIII) autoantibody is a rare but severe disorder. Challenges of the diagnosis and treatment is demonstrated by the case of a 67‐year‐old female without previous bleeding history, who suffered a huge muscular hematoma. Without blank subtraction 18% plasma FXIII activity was measured; however, after correction for blank the activity was below the limit of detection and the lack of fibrin cross‐linking in the patient's plasma confirmed the latter result. FXIII‐A2 antigen was not detectable by enzyme‐linked immunosorbent assay (ELISA); however, it was well detected by western blotting. The autoantibody showed high affinity toward FXIII‐A2. Its considerable inhibitory activity was demonstrated by high titer in Bethesda units and the low immunoglobulin G concentration required for inhibition. The main biochemical effect was the inhibition of Ca2+‐induced activation. Eradication therapy was only partially successful. Four months after the last hemorrhagic event the patient suffered deep vein thrombosis complicated by pulmonary embolism.

is a rare bleeding disorder characterized by low coagulant factor IX (FIX) levels. Mild haemophilia B (mHB) results in a significantly milder bleeding phenotype compared with moderate and severe forms. Muscular haematomas and joint bleeds or haemarthrosis are rare and usually induced by significant trauma.Such patients receive on-demand treatment. Prophylactic treatment is not usually recommended in mHB. 1 Molecular biology is recommended for investigating the aetiology of haemophilia B. Genotype may also be considered as a marker associated with bleeding phenotype. Our initial surprise came from reports of a mHB patient with